AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
Key Highlights
- ➤APEX Part B: All three zumilokibart regimens significantly beat placebo on EASI-75 at Week 16
- ➤Mid-dose zumilokibart regimen selected for Phase 3 development
- ➤Mid- and high-dose regimens significantly improved EASI 90/100 and I-NRS4 versus placebo
- ➤Zumilokibart demonstrated statistically significant EASI 90/100 and I-NRS4 improvements at all doses
- ➤Zumilokibart has an approximately 77-day human half-life, AbbVie (ABBV) says
Expert Statements
Kori Wallace, Vice president, global head of immunology clinical development, AbbVie
“Despite significant advances in atopic dermatitis, there remains an unmet need for therapies that provide meaningful disease control with greater convenience for patients.”
Kori Wallace, Vice president, global head of immunology clinical development, AbbVie
“These results support the potential of zumilokibart to rapidly improve both skin and itch.”
Kori Wallace, Vice president, global head of immunology clinical development, AbbVie
“Advancing the mid-dose regimen into Phase 3 and evaluating extended dosing intervals marks an important step in exploring a differentiated option for people living with AD.”
Melinda Gooderham, M.D., FRCPC, SKiN Centre for Dermatology and Queen's University, Ontario, Canada
“Atopic dermatitis is a chronic disease, and the frequency of administration can be an important consideration when selecting a long-term therapy.”
Melinda Gooderham, M.D., FRCPC, SKiN Centre for Dermatology and Queen's University, Ontario, Canada
“At Week 16, zumilokibart demonstrated improvements in skin clearance and itch.”
Melinda Gooderham, M.D., FRCPC, SKiN Centre for Dermatology and Queen's University, Ontario, Canada
“These findings support the further evaluation of zumilokibart as a long-term treatment for atopic dermatitis.”
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 PR Newswire
* Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity Index -75 (EASI-75) response rates versus placebo at Week 16 (1) * The mid-dose regimen was selected for Phase 3 development, supporting further evaluation of the efficacy, safety and dosing profile of zumilokibart (1) * Zumilokibart is a half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis (1) NORTH CHICAGO, Ill., Sept. 30, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating zumilokibart, in adult patients with moderate to severe atopic dermatitis (AD) will be presented as a late-breaker presentation at the 2026 Annual European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Sept. 30 – Oct. 3.
Get started
Create a free account to read the full story.